Shionogi's Mulpleta (lusutrombopag) Receives FDA Approval for Chronic Liver Patients in Adults
Shots:
- Mulpleta is approved based on two randomized- placebo-controlled trials (L-PLUS 1 & 2) involving 312 patients with platelets ≤50 x 109/L randomized 1:1 to receive 3mg once upto 7 days
- Oral recommendation is 3mg Q.D. with or without food for 7 days
- Results (Mulpleta vs PBO): In L-PLUS 1- No platelet transfusion (78% vs 13%) prior procedure; In L-PLUS 2- No platelet transfusion (65% vs 29%) prior procedure with common AE as headache
Ref: US FDA | Image: Forbes
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com